6‐Thioguanine — efficacy and safety in chronic active Crohn's disease
Klaus Herrlinger(Robert Bosch Hospital), Eduard F. Stange(John Radcliffe Hospital), Matthias Schwab(Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology), Juergen Schöelmerich(University of Regensburg), Aki Sebastian Ruhl(Heidelberg University), Peter Deibert(University of Freiburg), Roland Greinwald(Dr Falk Pharma (Germany)), Wolfgang E. Fleig(University Hospital Leipzig), Wolfgang Kreisel(University of Freiburg), Max Reinshagen(Evangelisches Krankenhaus Göttingen-Weende), Klaus Fellermann(Apple (Israel))
Cited by 75
Related Papers
A roadmap for graphene
|Nature|2012|9.1k
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
|Journal of Clinical Oncology|2006|1.2k
Reduced Paneth cell α-defensins in ileal Crohn's disease
|Proceedings of the National Academy of Sciences|2005|969
NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal α-defensin expression
|Gut|2004|798
A Chromosome 8 Gene-Cluster Polymorphism with Low Human Beta-Defensin 2 Gene Copy Number Predisposes to Crohn Disease of the Colon
|The American Journal of Human Genetics|2006|566